---
title: 'Intellia + Regeneron, Purdue, Amicus'
type: 'episode'
url: 'https://doc.social/episodes/intellia-regeneron-purdue-amicus'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-03-02'
audio: 'unavailable — the host retired the file'
---

# Intellia + Regeneron, Purdue, Amicus

CRISPR works, the opioid epidemic makes amends (sort of), and the SPAC that wasn’tFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesIntelliaPurdue PharmaAmicus SPACAbout the ShowLife Science Today is your source for stories…

## Summary

CRISPR works, the opioid epidemic makes amends (sort of), and the SPAC that wasn’t

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[Intellia](https://ir.intelliatx.com/news-releases/news-release-details/intellia-and-regeneron-announce-updated-phase-1-data)
[Purdue Pharma](https://www.biospace.com/article/releases/fda-approves-nalmefene-hcl-injection-2mg-2ml-1mg-1ml-for-the-treatment-of-known-or-suspected-opioid-overdose-with-natural-or-synthetic-opioids/?s=74)**
**[Amicus SPAC
](https://www.biospace.com/article/amicus-spac-spin-off-unravels-spooling-layoffs-and-restructuring/)
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.